The abrupt suspension of United States health aid to South Africa has sent shockwaves through the country’s HIV treatment programmes, putting hundreds of thousands of patients at risk. The decision, announced without warning last week, has left clinics scrambling for supplies and staff fearing the worst. In response, Britain has pledged an emergency package of £150 million through Commonwealth health partnerships, but activists warn it may not be enough to plug the gap left by Washington.
For years, South Africa has relied on the US President’s Emergency Plan for AIDS Relief (PEPFAR) to fund antiretroviral drugs, testing kits, and community health workers. The programme has been a lifeline for the 7.8 million South Africans living with HIV. Now, with the tap turned off, the consequences are immediate. At a clinic in Soweto, nurse Thandi Mokoena described the scene as “chaotic”. “Patients are being turned away. Some have been on treatment for years and now face the risk of resistance if they miss doses,” she said.
The US administration cited concerns over South Africa’s land reform policies and alleged mismanagement of funds as reasons for the cut. But critics argue the move is politically motivated and disregards the humanitarian cost. Dr. John Makhubu, a leading HIV researcher at the University of Cape Town, called it “a betrayal of the global health compact”. He warned that the disruption could undo decades of progress and lead to a resurgence of infections.
Britain’s intervention, while welcome, is seen as a stopgap. The Department of Health and Social Care confirmed that the new funding would be channelled through the Commonwealth Health Partnership, focusing on maintaining treatment regimens and strengthening local healthcare systems. International Development Minister Anneliese Dodds said: “The UK stands with South Africa. We will not allow political disputes to cost lives.” But the pledge represents only a fraction of what PEPFAR provided an estimated $400 million annually.
Labour unions and health campaigners have called for a long-term strategy. The National Union of Public Servants, which represents many health workers, issued a statement demanding that the government “urgently fill the funding gap” and “hold the US to account”. Meanwhile, the Treatment Action Campaign launched a petition calling for the UK to convene a donor conference.
For the patients at the sharp end, the numbers are stark. In the province of KwaZulu-Natal, where HIV prevalence is highest, some clinics have already suspended new patient enrollments. At the Thembalethu Clinic in Durban, volunteer counsellor Sipho Dlamini described the mood as “fearful”. “People are scared they will die because of politics,” he said. “We need a sustainable solution not just a sticking plaster.”
The row has also reignited debate about aid dependency. South Africa’s health department has pledged to redirect domestic resources, but with the economy still struggling and unemployment above 30 per cent, the capacity is limited. The Treasury estimates that maintaining the current HIV programmes would cost an additional R4 billion a year a sum not easily found in a tight budget.
As Britain steps in, questions remain about whether other Commonwealth nations will follow suit. Canada and Australia have so far not announced additional support. For now, the focus is on keeping patients alive. “Every day counts,” said Dr. Makhubu. “We are in a race against time.”
